TITLE 1 Beta-blocker exposure is associated with nonunion in a geriatric cohort of 253,266 2 extremity fractures 3 4 **AUTHORS** Lillia Steffenson¹, Brook Martin¹, Adam Kantor¹, Dillon O'Neill¹, Luke Myhre¹, Tyler 5 Thorne¹, David Rothberg¹, Thomas Higgins¹, Justin Haller¹, Lucas Marchand¹ 6 7 **AFFILIATIONS** 1. University of Utah 8 9 **CORRESPONDING AUTHOR** Lillia Steffenson, MD 10 Department of Orthopaedics 11 University of Utah School of Medicine 12 590 Wakara Way 13 Salt Lake City, UT 84108 14 Phone: (801) 587-7100 15 Fax: 801-587-5411 16 17 E-mail: Lillia.Steffenson@hsc.utah.edu 18 Conflict of Interest: The authors have declared that no conflict of interest exists. 19

20

ABSTRACT

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

Previously published animal studies have shown positive skeletal effects with local or systemic administration of beta blockers (BBs). However, population studies have shown mixed effects on bone mineral density (BMD) and fracture risk with BB use. The goal of this study was to evaluate whether exposure to BB is associated with fracture nonunion. Fee-for-service Medicare beneficiaries with an extremity fracture were identified by International Classification of Diseases (ICD)-10 and current procedural terminology (CPT) codes from 2016-2019. Charlson Comorbidity Index (CCI) was assigned using diagnoses prior to index fracture and nonunion identified by ICD-10 or CPT codes within one year from index fracture diagnosis. Patients were classified by BB exposure based on Part D (Pharmacy) claims between 90 days prior to and one year following index fracture. Chi square and Student's T-tests were performed on categorical and continuous variables, respectively. Logistic regression was performed to evaluate the association between BB use and nonunion, controlling for age, sex, race, and comorbidity. Total number of fractures meeting inclusion criteria was 253,266 with 45% of patients having used a BB during the study period. The incidence of nonunion was 3.9% overall. BBs were associated with a 13% increase in non-union for all fracture types, after controlling for age, sex, fracture location, and CCI (OR 1.13 [CI 1.06-1.20], p<.001). Results of this study suggest a negative influence of BB on bone healing, contrary to results of previously published animal models and epidemiologic observations, and demonstrate that BB use during fracture care is associated with significant increase in incidence of nonunion.

INTRODUCTION

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

Beta blockers are a class of medications which act as antagonists to beta-adrenergic receptors of the sympathetic nervous system (SNS). These receptors are found primarily in mesenchymal tissue types including cardiac, pulmonary, and vascular smooth muscle as well as skeletal muscle, adipose and osseous tissue. There are three subtypes of this adrenergic stimulated G-protein coupled receptor, beta-1, beta-2, and beta-3 receptor, and effects vary due to the distribution of these receptors in different tissues. Beta-1 receptors found within the heart increase heart rate and contractility causing a rise in cardiac output while those in the kidneys promote renin secretion. When stimulated, beta-2 receptors result in bronchodilation, vasodilation, and enhanced skeletal muscle contraction in addition to gluconeogenesis and insulin secretion. Beta-3 receptors within fat tissue increases lipolysis and relaxation of bladder smooth muscle. Skeletal homeostasis is maintained by the constant balance of activity between osteoblasts (bone forming cells) and osteoclast (bone resorbing cells). This mechanism may alter bone mineral density due to changes in activity or underlying physiologic demands (1, 2). Within osseous tissue, beta-2 adrenergic receptors (β2AR s) are found on both osteoblasts and osteoclasts where β2AR activation by norepinephrine and epinephrine induces bone loss through RANK ligand-mediated activation of osteoclasts and inhibits osteoblast proliferation (3). In mice, deletion of adrenergic beta-2 receptor (Adrb2) leads to greater trabecular bone microarchitecture and bone mass within both femur and vertebrae. Addition of beta-1 receptor knockout to the model results in loss

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

of this phenotype and overall decreased total bone volume and cortical thickness (4) suggesting differential effects of these two receptor subtypes. Observational studies in humans have similarly identified that individuals taking beta blocker medications have higher bone mineral density (BMD) and lower fracture risk (5-13). Considering post-menopausal women have been found to have higher sympathetic activity compared to pre-menopausal women and sympathetic nerve activity is inversely correlated with trabecular bone volume (14), these findings have renewed interest in modulating adrenergic signaling as a potential intervention for primary osteoporosis prevention (2). One such study by Khosla et al., saw increases in distal radius BMD in post-menopausal women treated with 20 weeks of atenolol (15). At present, there are no human studies evaluating the effect of beta blockers on fracture outcome. However, in a murine fracture model, low dose propranolol over 9 weeks increased periosteal and endosteal bone formation and improved consolidation of fracture callus. In the absence of fracture, torsional strength of rat femurs was increased by 33% with propranolol (16). In another study, intraperitoneal administration of the cardio selective BB nebivolol, had a dose dependent increase in histologic osseous healing in rat femur fractures stabilized with intramedullary Kirschner wires, whereas cartilage formation was greater in the control group (17). However, rat osteotomy healing with intraperitoneal propranolol administration in a third study did not change final torsional strength or union rates, despite a nonsignificant increase in callus strength at 5 weeks in the propranolol group (18).

The purpose of the present study was to evaluate the association between beta blocker exposure and fracture healing in humans, given the evidence for anabolic osseous effect in prior observational and animal studies.

METHODS

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

Study Cohort

A retrospective analysis of a convenience cohort drawn from Medicare beneficiaries with a Part B (provider service) claim for back pain and/or osteoporosis from 2016-2019 was performed. Patients were included if they were over 65 years of age and had a Part B inpatient or outpatient claim for a femur, tibia/fibula, forearm, or humerus fracture identified by International Classification of Diseases and 10th Revision (ICD-10) codes and Current Procedural Terminology codes (CPT) (Supplemental Table 1). From this initial cohort, patients were then excluded if they were less than 65 years old at the time of fracture, had Medicare through either the end stage renal disease (ESRD) or Social Security Disability Insurance (SSDI) entitlement programs, were not enrolled in Medicare Part D coverage, had follow-up of less than 1 year (e.g. fracture occurred in 2019), died within a year of fracture, had a concurrent or prior diagnosis of nonunion by ICD-10 codes at the time of index fracture, or had insufficient 1 year claims history prior to fracture to calculate comorbidity index. The cohort was screened for duplicate claims which were excluded from final analysis. Patient demographics including age, sex, race (simplified grouping as "White", "Black", or "Other"), and Charlson Comorbidity Index (CCI) (19) were collected.

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

The primary outcome of this study was fracture status one year following index injury. dichotomized as union or non-union. Non-union was identified in the final cohort using CPT codes for nonunion and ICD-10 codes (Supplemental Table 1). A union of the fracture was assumed if the beneficiary claims history did not include a non-union diagnosis. The analytical cohort was grouped based on exposure to beta blockers (supplemental table 2) and statin medications for comparison and categorized as pre-fracture use only, post-fracture use only, or both pre- and post-fracture exposure. Pre-fracture exposure was defined as a prescription claim within 90 days prior to index fracture. Subgroup analyses were also performed to evaluate differences in immediate post-fracture exposure within 90 days of index fracture, difference in non-union within each specific type of fracture, between selective vs. non-selective beta blockers, then beta blockers were combined with statins, and based number of beta blocker (statin) prescriptions filled served as a proxy for an exposure "dose-response", Statistical Analysis Descriptive statistics were presented for patient demographics, fracture types, rates of union and non-union, and medication use. Chi square and Student's T-tests were performed on categorical and continuous variables, respectively. Separate multivariable logistic regression models with robust standard errors were then used to describe the association between each medication class and fracture status at 1-year, both overall

and within each fracture type, controlling for age, sex, race and CCI. Similar logistic regression models were used to examine the relationship between medication timing and non-union while controlling for age, sex, race, CCI, and fracture type. Analyses were conducted using Stata 17.0 MP (College Station, TX) accessed through Medicare's Virtual Research Data Center, and presented as odds ratios with hypotheses based on an alpha level of 0.001. A power analysis performed using a t beta value of 0.80 indicated at least 5300 patients needed in each group to detect a 1% difference in nonunion.

RESULTS

Starting with 1,079,157 extremity fractures, a total of 253,266 fractures met inclusion criteria (Figure 1) with 85,114 femur fractures, 73,444 forearm fractures, 41,097 humerus fractures and 53,373 tibia or fibula fracture. Overall incidence of nonunion was 3.9%. The highest incidence of nonunion was observed among humerus fractures at 6.2%. Examining patient demographics, those diagnosed with nonunion were younger by an average of 2 years (p<.001) and there was a higher proportion of males (21.3% vs 17.8%, p<.001) (Table 2). There were no significant differences in race or CCI by fracture outcome.

Exposure to beta blockers and statins was greater in males, patients with higher CCI, and black race (Table 3).

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

After controlling for age, sex, race, comorbidity, and fracture type, the multivariable model did not reveal a significant association between statin use and nonunion (OR 1.05 [95%Cl 1.01 – 1.47] p-value=0.018). However, beta blockers were associated with an 11% increase in nonunion diagnosis (OR 1.11 [95%Cl 1.06-1.15] <0.001) regardless of the number of prescriptions in the follow up period (Table 4). When excluding those taking statins, the increase of nonunion among beta blocker users was 13% (OR 1.13) [95% CI 1.06-1.20]). Subgroup analysis: There was no obvious pattern in the likelihood of non-union based on the timing of betablocker use relative to when the fracture occurred (Table 4). There was no difference between selective (OR 1.12 [95%CI 1.07 – 1.17]), non-selective (OR 1.15 [95%CI 1.07 - 1.23]) or combined selective and non-selective (OR 1.15 [95%CI 0.99 - 1.34] BB exposure on fracture status at 1 year (Table 5). All three categories had a higher risk compared to the non-user group. Combined exposure of beta blocker and statin use had a modest increase in nonunion (OR 1.19 [1.12-1.25 p<0.001] compared to nonusers but was not significantly more than taking either beta-blockers or stains alone (Table 5). Neither a greater number of beta blockers prescription nor statin prescriptions filled was associated with a greater likelihood of non-union (Table 4). Sensitivity analysis for unobserved confounding: We performed a sensitivity analysis to explore the possibility for unobserved confounders to account for the higher risk of non-union found among beta-blocker users at 1 year. By definition, a confounder is a factor associated with both the exposure (beta blocker use) and the outcome (fracture non-union). A confounder sensitivity analysis reports the magnitude that these associations require in order to nullify the association that we observed. In our analysis, we found that a hypothetical unobserved factor with an OR of 1.46 [or a lower CI limit of 1.31] for an association with both the exposure and outcome was required to render our findings for beta blockers null. As shown in Figure 2, a lesser association with the exposure requires an exponentially greater association with the outcome (and vice versa).

DISCUSSION

Age-related bone loss is multi-factorial. The primary mechanism in both men and women is gonadal sex steroid deficiency (20). While this change is more pronounced in post-menopausal women, men also experience age related declines in bone density (21, 22). In women this can be attenuated by hormone replacement therapy (HRT) (23-25), due to HRT stimulation of growth hormone, TGFB and IGF-1 production (26-28). Use of HRT to treat osteopenia or osteoporosis, however, is associated with increased risk of cardiovascular events and breast cancer and is not recommended as first line therapy (21). Geriatric patients also have increased sympathetic nervous system activity, contributing to the higher risk of multi organ system pathophysiologic changes with aging (29, 30) as well as age-related bone loss (14).

Multiple epidemiologic studies from 2000-2015 identified that patients taking BBs have higher BMD and lower fracture risk (5-13). Preceding data from murine models also

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

found an anabolic effect of beta blockers on bone, with osteotomized rats exposed to BB having greater callus formation and improved biomechanics compared to controls (16, 17). The proposed mechanism of this observation is antagonism of normal skeletal B2AR function in stimulating osteoclasts (31). While some animal studies similarly found positive effects of beta blockers on osteotomy healing, there is competing basic science evidence for this association across rodent models (18, 32-35). The aim of this study was to further evaluate the association between beta blockers and fracture fracture healing in humans. In the present study, there was a modest but significant increase in the diagnosis of nonunion among patients taking beta blockers. There was no difference between cardioselective and nonselective beta blocker exposure. This finding is supported by a previous database study, which also observed an association between cardiac medications and diuretics and nonunion (36). The present study focused on beta blocker use given the abundance of basic science research regarding the mechanism of action of beta blockers in modulating osseous physiology. Notably, the study by Buccheit et al., did not detect higher incidence of nonunion with steroid medications or immunosuppressant exposure following fracture treatment. Our findings contradict the existing literature regarding the osseoanabolic effect of beta blockers and ongoing research regarding beta blockers as a potential primary preventative agent for osteopenia and osteoporosis (2). However, it is important to consider that adrenergic receptors have differential effects depending on the subtype

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

targeted by pharmacologic interventions. For example, the primary subtype expressed in bone is \$2AR, which when stimulated by glucocorticoids results in lower bone density, while co-treatment with propranolol was protective against bone loss (37). On the other hand, beta-1 receptor knockout mice at 4 months have lower BMD, lower bone volume, and trabecular volume when compared to both wild type (WT) and Adbr2 knockout mice (4), indicating that normal adrenergic beta-1 receptor function is important for maintenance of bone volume and density in a murine model. Furthermore, in the same study by Pierroz et al., Adbr1b2^{-/-} mice had persistent decreases in whole body BMD up to 40 and 50 weeks of age, but this difference diminished as the mice approached 60 weeks of age. Based on these findings, the authors propose that beta 2 signaling is higher in bone of wild type mice, but beta-1 signaling may be just as important in the regulation of skeletal tissue. Additionally, one must consider the condition where SNS activation is known to improve fracture healing. In moderate and severe traumatic brain injury (TBI), fracture healing is accelerated in both clinical studies and murine models (38-41). TBI results in several pathophysiologic effects, but largely increases SNS activity. In an unpublished independent study by Jahn et al., the authors found that increased NE-Arb2 signaling mediates TBI-induced skeletal manifestations in both bone remodeling and regeneration. Furthermore, the study demonstrates that Adrb2 plays an age-dependent and pharmacologically targetable role in fracture healing by promoting callus vascularization under conditions of increased sympathetic tone. The beneficial effect of TBI on bone regeneration was also completely absent in mice lacking Adrb2 (medRxiv

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

BIORXIV/2023/548550). These findings suggest an essential function of Adrb2 in promoting bone repair and provide evidence that in a hyperadrenergic state, activity by these receptors may be essential for normal bone healing. The challenge in these large observational studies remains the difficulty in determining the medication effect, versus a reflection of the patient's overall health status that is not completely captured by comorbidity indices. The studies in question all use different methods to control for comorbidities, which may confuse the results. It is also difficult to discern if route of medication administration and age of the specimens may change the central and peripheral effects of these medications. Finally, the present study is limited as it is a convenience cohort of Medicare patients is not generalizable to the general population. **AUTHOR CONTRIBUTIONS** Authorship note: LS and BM collaborated on study design, LM supervised the study, BM performed statistical analysis, LS prepared the manuscript which was reviewed and edited by the remaining authors. **ACKNOWLEDEMENT** Funding support provided by internal grant from the LS Peery MD Discovery Program of the University of Utah's Department of Orthopaedics.

REFERENCES

272

- 1. Takeda S, et al. Leptin regulates bone formation via the sympathetic nervous system. Cell.
- 274 2002;111(3):305-317.
- Karsenty G, and Khosla S. The crosstalk between bone remodeling and energy metabolism: A
- translational perspective. Cell Metab. 2022;34(6):805-817.
- Elefteriou F, et al. Leptin regulation of bone resorption by the sympathetic nervous system and
- 278 CART. Nature. 2005;434(7032):514-520.
- 279 4. Pierroz DD, et al. Deletion of β-adrenergic receptor 1, 2, or both leads to different bone
- phenotypes and response to mechanical stimulation. J Bone Miner Res. 2012;27(6):1252-1262.
- 5. Schlienger RG, et al. Use of beta-blockers and risk of fractures. JAMA. 2004;292(11):1326-1332.
- 282 6. Pasco JA, et al. Beta-adrenergic blockers reduce the risk of fracture partly by increasing bone
- 283 mineral density: Geelong Osteoporosis Study. J Bone Miner Res. 2004;19(1):19-24.
- 7. L. Rejnmark, et al. Fracture risk in perimenopausal women treated with beta-blockers Calcif
- 285 Tissue Int, 75 (2004), pp. 365-372
- 8. Wiens M, et al. Effects of antihypertensive drug treatments on fracture outcomes: a meta-analysis
- 287 of observational studies. J Intern Med. 2006;260(4):350-362.
- 9. Graham S, et al. The effect of beta-blockers on bone metabolism as potential drugs under
- investigation for osteoporosis and fracture healing. Expert Opin Investig Drugs. 2008;17(9):1281-
- 290 1299.
- 291 10. Yang S, et al Association between beta-blocker use and fracture risk: the Dubbo Osteoporosis
- 292 Epidemiology Study. Bone. 2011;48(3):451-455.
- 293 11. Yang S, et al. Association between beta-blockers and fracture risk: a Bayesian meta-analysis.
- 294 Bone. 2012;51(5):969-974.
- 12. Toulis KA, et al. β-Adrenergic receptor antagonists and fracture risk: a meta-analysis of
- selectivity, gender, and site-specific effects. Osteoporos Int. 2014;25(1):121-129.
- 13. Schlienger RG, et al. Use of beta-blockers and risk of fractures. JAMA. 2004;292(11):1326-1332.
- 14. Farr JN, et al. Relationship of sympathetic activity to bone microstructure, turnover, and plasma
- osteopontin levels in women. J Clin Endocrinol Metab. 2012;97(11):4219-4227.

- 15. Khosla S, et al. Sympathetic β1-adrenergic signaling contributes to regulation of human bone
 metabolism. J Clin Invest. 2018;128(11):4832-4842.
- 302 16. Minkowitz B, et al. Effects of propranolol on bone metabolism in the rat. J Orthop Res. 1991;9(6):869-875.
- Metineren H, et al. Effect of nebivolol on fracture healing: An experimental rat model. Adv Clin
 Exp Med. 2017;26(6):919-923
- 306 18. Smitham P, et al. Low dose of propranolol does not affect rat osteotomy healing and callus strength. J Orthop Res. 2014;32(7):887-893.
- 19. Quan H, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10
 administrative data. Medical Care 2005. Nov; 43(11):1073-1077.
- 20. Khosla S, Riggs BL. Pathophysiology of age-related bone loss and osteoporosis. Endocrinol
 Metab Clin North Am. 2005 Dec;34(4):1015-30, xi.
- 312 21. Khosla S, Amin S, Orwoll E. Osteoporosis in men. Endocr Rev. 2008;29(4):441-464.
- 313 22. Khosla S. Update in male osteoporosis. J Clin Endocrinol Metab. 2010;95(1):3-10.
- Tobias JH, Compston JE. Does estrogen stimulate osteoblast function in postmenopausal
 women?. Bone. 1999;24(2):121-124.
- 24. Lindsay R, et al. Long-term prevention of postmenopausal osteoporosis by oestrogen: evidence
 for an increased bone mass after delayed onset of oestrogen treatment. Lancet.
 1976;1(7968):1038–1041.
- 319 25. Genant HK, et al. Quantitative computed tomography of vertebral spongiosa: a sensitive method for detecting early bone loss after oophorectomy. Ann Intern Med. 1982;97(5):699–705.
- 26. Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in
 experimental animals and the human. Endocr Rev. 1998;19(6):717-797.
- 27. Ernst M, Heath JK, Rodan GA. Estradiol effects on proliferation, messenger ribonucleic acid for
 collagen and insulin-like growth factor-I, and parathyroid hormone-stimulated adenylate cyclase
 activity in osteoblastic cells from calvariae and long bones. Endocrinology. 1989;125(2):825-833.

326 28. Oursler MJ, et al. Modulation of transforming growth factor-beta production in normal human 327 osteoblast-like cells by 17 beta-estradiol and parathyroid hormone. Endocrinology. 328 1991;129(6):3313-3320. 329 29. Rossouw JE, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal 330 women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 331 2002;288(3):321-333. 332 30. Pfeifer MA, et al. Differential changes of autonomic nervous system function with age in man. Am 333 J Med. 1983;75(2):249-258. 334 31. Jones PP, et al. Age-related increase in muscle sympathetic nerve activity is associated with 335 abdominal adiposity. Am J Physiol. 1997;272(6 Pt 1):E976-E980. 336 32. Bonnet N, et al. Protective effect of beta blockers in postmenopausal women: influence on 337 fractures, bone density, micro and macroarchitecture. Bone. 2007;40(5):1209-1216. 338 33. Suzuki A, et al. Catecholamines stimulate the proliferation and alkaline phosphatase activity of 339 MC3T3-E1 osteoblast-like cells. Bone 1998;23:197-203. 340 34. Zeman RJ, et al. Clenbuterol, a beta 2-receptor agonist, reduces net bone loss in denervated 341 hindlimbs. Am J Physiol 1991;261:E285-9. 342 35. Pataki A, et al. Anabolic effects of beta2-agonists, formoterol and salbutamol on cancellous bone 343 of ovariectomized rat. Bone 1996;9:A116. 344 36. Buchheit T, et al. Opioid exposure is associated with nonunion risk in a traumatically injured 345 population: An inception cohort study. Injury. 2018;49(7):1266-1271. 346 37. Ma Y, et al. β2-Adrenergic receptor signaling in osteoblasts contributes to the catabolic effect of 347 glucocorticoids on bone. Endocrinology. 2011;152(4):1412-1422. 348 38. Perkins R, Skirving AP. Callus formation and the rate of healing of femoral fractures in patients 349 with head injuries. J Bone Joint Surg Br. 1987;69(4):521-524. doi:10.1302/0301-350 620X.69B4.3611150 351 39. Yang C, et al. The effect of traumatic brain injury on bone healing from a novel exosome centered

perspective in a mice model. J Orthop Translat. 2021;30:70-81. Published 2021 Sep 23.

352

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

40. Bajwa NM, et al. Long-term Consequences of Traumatic Brain Injury in Bone Metabolism. Front Neurol. 2018;9:115. Published 2018 Mar 5. 41. Locher RJ, et al. Traumatic brain injury and bone healing: radiographic and biomechanical analyses of bone formation and stability in a combined murine trauma model. J Musculoskelet Neuronal Interact. 2015;15(4):309-315. TABLE AND FIGURE LEGENDS Figure 1. Consort diagram of study cohort. Patients were excluded if they were eligible for Medicare through social security disability (SSDI), end-stage renal disease (ESRD) entitlements, had insufficient Part D pharmacy data or at least 1 year of claims data. Table 1: Fracture union status at 1-year, within fracture type cohort. Table 2: Demographic Characteristics between Medicare beneficiaries who did or did not experience non-union within one year following fracture. Table 3. Demographic Characteristics between Medicare beneficiaries based on medication exposure. Table 4: Association of select medications on non-union, controlling for age, sex, race, Charlson comorbidity index (365-day lookback), and fracture type. (Prescription = Rx) Table 5: Sub analysis of combined medication exposure and beta blocker class on non-union, controlling for age, sex, race, Charlson comorbidity index (365-day lookback), and fracture type.

- 378 Figure 2. Sensitivity analysis examining the relationship between potential unaccounted
- 379 confounders.

Figure 1. Consort diagram of study cohort. Patients were excluded if they were eligible for Medicare through social security disability (SSDI), end-stage renal disease (ESRD) entitlements, had insufficient Part D pharmacy data or at least 1 year of claims data.




Table 1. Fracture union status at 1-year, within fracture type cohort.

Fracture Cohort	Union	Non union	Total
Femur	82,059 (96.4%)	3,055 (3.6%)	85.114
Forearm	73,444 (97.2%)	2,144 (2.8%)	75,588
Humerus	38,566 (93.8%)	2,531 (6.2%)	41,097
Fibula/Tibia	51,041 (95.6%)	2,332 (4.4%)	53,373

Table 2. Demographic Characteristics between Medicare beneficiaries who did or did not experience non-union within one year following fracture.

	Fractu			
	Union	Non-union	Total	p-value
	(n=243,319)	(n=9,947)	(n=253,266)	
Age (mean)	79.4	77.3	79.3	<0.001
Female, %	82.2	77.7	82.0	<0.001
Door (2 groups) 0/				
Race (3 groups), %			24.2	0.407
White	91.6	91.6	91.6	0.407
Black	3.3	3.1	3.2	
Other	5.2	5.4	5.2	
Comorbidity 365-day lookback,				
%				
0	21.7	21.4	21.7	0.739
1	20.6	20.5	20.6	
2	57.8	58.1	57.8	
Medication use				
Beta blocker, %	45.0	47.3	45.1	< 0.001
Statin, %	53.3	56.6	53.4	< 0.001

Table 3. . Demographic Characteristics between Medicare beneficiaries based on medication exposure.

	Beta B	eta Blocker p Statin value		p value		
	No	Yes	value	No	Yes	Value
N	139,096	114,170		117,921	135,345	
Age, mean (sd)	78.6	80.2		79.9	78.9	
	(8.1)	(7.8)		(8.5)	(7.6)	
Female, %	83.1	80.7	p<.001	84.8	79.6	p<.001
Race (3 groups),						
White	91.6	91.6		92.2	91	
Black	2.9	3.6		3	3.4	
Other	5.5	4.8	p<.001	4.8	5.5	p<.001
Comorbidity 365-day						
lookback, %						
0	27.8	14.2		27.8	16.3	
1	22.9	17.6		22.5	18.9	
2	49.2	68.2	p<.001	49.7	64.8	p<.001

Table 4. Association of select medications on non-union, controlling for age, sex, race, Charlson comorbidity index (365-day lookback), and fracture type. (Prescription = Rx)

Model	Factor	OR (95%CI)	Rate	p- value
Non-union as a function of any exposure to medication within 1 year of fracture.	Beta- blocker	1.11 (1.06 – 1.15)	3.7 vs.3.4	<0.00
	Statin	1.05 (1.01 – 1.10)	3.6 vs 3.5	0.018
Non-union as a function of beta blocker prescriptions filled (dose response) conditional on beta blocker use	1-4 Rx	1.00 (ref)	4	
	5-6 Rx	0.96 (0.89 – 1.03)	3.8	0.258
	7+ Rx	0.93 (0.87 – 1.00)	3.7	0.045
Non-union as a function of statin prescriptions filled (dose response) conditional on statin use	1 -4 Rx	1.00 (ref)	4.1	
	5 Rx	0.88 (0.83 – 0.95)	3.6	0.001
Non-union as a function pre and post-fracture beta blocker use	None	1.00 (ref)	3.5	
	Pre fracture beta-blocker use only	1.15 (0.97 – 1.35)	4.0	0.110
	Post fracture beta-blocker use only	1.14 (1.07 – 1.22)	3.9	<0.00
	Pre and post fracture beta-blocker use	1.12 (1.07 – 1.17)	3.9	<0.00

Table 5. Sub analysis of combined medication exposure and beta blocker class on non-union, controlling for age, sex, race, Charlson comorbidity index (365-day lookback), and fracture type.

Model	Factor	OR (95%CI)	Rat e	p- value
Non-union as a function of interaction between beta-blocker use and statin use	None	1.00 (Ref)	3.4	
	Beta-blocker	1.13 (1.06 - 1.20)	3.8	<0.00
	Statin	1.08 (1.02 - 1.14)	3.6	0.009
	Beta-blocker & statin	1.19 (1.12 - 1.25)	3.9	<0.00
Non-union as a function of beta-blocker type (selective or non-selective), conditioned on use of beta blocker	Select beta- blocker	1.00 (Ref)	3.8	-
	Non-select beta- blocker	1.03 (0.96 - 1.11)	3.9	0.355
	Select & non- select beta- blocker	1.04 (0.89 - 1.21)	4	0.621

Figure 2. Sensitivity analysis examining the relationship between potential unaccounted confounders.

